Annovis Bio, Inc. ANVS
1.31
(0.02)
(1.50%)
as of 25 Sep
- Market cap
- $56.8M
- P/E
- 0.0×
Follow ANVS
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.73 | 0.09 | 0.37 | 14.04 | 30.54 | 4.68 | 2.39 | 3.59 | 5.80 |
Net Debt/EBITDA |
0.51 | 0.05 | (0.31) | 1.22 | 3.14 | 1.11 | 0.13 | 0.40 | 0.66 |
Debt/Assets |
0.00% | 0.00% | 44.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | (0.06) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.79 | 0.78 | 0.48 | 0.73 | 0.63 | 0.68 | 0.71 | 0.89 | 0.89 |
Capex/Depreciation |
— | — | 0.00 | 0.00 | — | — | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 9.37% | 9.81% | 12.26% | 1,055.05% | (55.68%) | (69.57%) | (546.40%) | (3,158.89%) | (220.61%) | |
| (333.64%) | (2,799.61%) | (169.68%) | (118.27%) | (53.54%) | (61.76%) | (243.15%) | (203.78%) | (164.85%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
516.11% | 138.11% | 78.45% | (72.43%) | (32.56%) | (89.43%) | (947.92%) | (244.81%) | (165.39%) |
Average Days of Receivables |
— | — | 0.00 | — | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.08) | (2.01) | (1.68) | (0.63) | (1.20) | (2.12) | (4.43) | (1.80) | (1.25) |
Cash per Share |
0.05 | 0.13 | 0.01 | 1.28 | 5.99 | 3.48 | 0.64 | 0.87 | 0.95 |
Shareholders Equity per Share |
(0.02) | (27.32) | (30.31) | 1.20 | 5.83 | 3.47 | (0.86) | 0.76 | 0.82 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.02) | (27.32) | (30.31) | 1.20 | 5.83 | 3.47 | (0.86) | 0.76 | 0.82 |
Free Cash Flow |
(0.54) | (0.56) | (0.48) | (3.97) | (9.13) | (17.31) | (39.97) | (21.89) | (25.62) |
Working Capital |
(0.13) | (0.52) | (1.26) | 7.54 | 44.50 | 28.32 | 5.93 | 10.04 | 17.45 |
Net Current Asset Value |
(0.13) | (7.59) | (8.95) | 7.54 | 44.50 | 28.32 | (7.75) | 9.31 | 16.85 |
| Other line items | |||||||||
Quick Ratio |
0.71 | 0.06 | 0.37 | 13.96 | 30.33 | 3.69 | 1.34 | 2.72 | 5.37 |
Depreciation/Fixed assets |
— | — | 0.00 | 0.00 | — | — | — | — | — |
Cash ROIC |
(249.77%) | 7.39% | 5.90% | (25.43%) | (10.13%) | (30.53%) | 2,002.27% | (110.25%) | (70.42%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.08) | (2.01) | (1.68) | (0.63) | (1.20) | (2.12) | (4.43) | (1.80) | (1.25) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
0.07 | 0.07 | 0.65 | 0.79 | 0.52 | 2.32 | 2.63 | 1.80 | 2.45 |
Average Assets |
0.20 | 0.03 | 0.58 | 4.62 | 27.06 | 41.01 | 23.12 | 12.07 | 17.50 |
Average Common Equity |
(7.28) | (7.28) | (8.09) | (0.52) | 26.02 | 36.41 | 10.29 | 0.78 | 13.08 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates